Oncovision

Executive Summary

Oncovision is a Spanish medical technology company specializing in molecular imaging devices and radiopharmaceuticals for cancer and neurodegenerative disease diagnosis and treatment. Founded in 2004 and headquartered in Valencia, the company has developed a portfolio that includes dedicated PET and gamma imaging systems for breast cancer, radioguided surgery tools, and brain imaging solutions. By combining advanced imaging hardware with targeted radiopharmaceuticals, Oncovision aims to improve early detection and precision medicine in oncology and neurology. With its focus on niche imaging modalities, the company is positioned to address unmet needs in breast cancer diagnosis and surgical guidance, potentially reducing the need for invasive procedures and improving patient outcomes. Looking ahead, Oncovision's growth depends on regulatory approvals and clinical adoption of its products. The company's lead platforms—such as its dedicated breast PET imager and radioguided surgery probes—require continued validation through clinical studies and market expansion. As a private firm, its progress may be supported by strategic partnerships or funding rounds. While specific near-term milestones are not publicly disclosed, the company is likely pursuing CE marking under MDR for European markets and seeking FDA clearance for its key devices. In the neuroimaging space, advancements in radiopharmaceuticals for neurodegenerative diseases could open additional opportunities. The overall outlook is promising given the increasing demand for non-invasive cancer diagnostics and the trend towards personalized medicine, though execution risks remain regarding regulatory timelines and commercial uptake.

Upcoming Catalysts (preview)

• Q3 2026CE Mark for Next-Generation Breast PET Imager70% success
• H2 2026FDA 510(k) Clearance for Radioguided Surgery Probe60% success
• Q4 2026Clinical Readout for Brain Amyloid PET Tracer50% success